Retatrutide

What retatrutide is

Retatrutide is a lab-made peptide that has been tested in people in phase 1, phase 2 and phase 3 trials. The two phase 2 trials were randomized and controlled. One was in adults with obesity and one was in adults with type 2 diabetes. Three phase 3 trials were published in 2026 [19], [20], [21]. As of October 2026, it is not approved for medical use in people anywhere in the world. That includes the FDA, the EMA in Europe and the MHRA in the UK.

A peptide is a short chain of amino acids, the building blocks of protein. This one is a single molecule, and its development code is LY3437943. It is an agonist, a compound that switches a receptor on. A receptor is the spot on a cell where a hormone attaches. Retatrutide acts on three receptors for hormones that control metabolism:

• the GLP-1 receptor (GLP-1 is short for glucagon-like peptide-1)
• the GIP receptor (GIP is short for glucose-dependent insulinotropic polypeptide)
• the glucagon receptor

In the trials run so far, it was given once a week as a shot under the skin.

Researchers call molecules of this kind “unimolecular polyagonists”. Each is one peptide built to switch on more than one gut hormone receptor at once, in place of a mix of separate drugs [2]. Early research on the idea set out the reasoning. Each pathway does a different job by itself. GLP-1 curbs appetite. GIP prompts insulin release and signals in fat. Glucagon acts on energy use and the liver. Put together, they may give a bigger effect than any one alone [2].

The lab pharmacology of the compound was first described in print in 2022. That paper covered how it binds to its receptors. It also traced the path from bench chemistry to the first proof of concept in people [5]. A phase 3 program called TRIUMPH, meant to support approval, came next [18]. Its first two trials were published in September 2026 [20], [21]. Commentators have called it the first agent of its kind to get this far in human testing [11]. Later narrative reviews have followed its progress closely [12].

Everything in this guide comes from published, peer-reviewed human trials or from lab pharmacology. It is here for research and learning only.

How much research there is

Two phase 2 trials and three published phase 3 trials in people, all paid for by the company that makes the drug.

Question	Answer
Stage of the evidence	Phase 2 is finished. Three phase 3 trials were published in 2026: TRANSCEND-T2D-1, TRIUMPH-1 and TRIUMPH-2 [19], [20], [21]
Kinds of studies	Randomized, double-blind human trials with a placebo group, from phase 1 to phase 3. The phase 2 type 2 diabetes trial also had an active drug group [7]. Lab pharmacology and mechanism studies back these up
Who was tested	Adults who had obesity but not diabetes, adults who had type 2 diabetes, and adults who had both
Checked by others	Results held up in separate groups, people with obesity and people with type 2 diabetes, and from phase 2 to phase 3. Independent systematic reviews and meta-analyses also looked at them [13], [17]
Who paid for the trials	Every published trial comes from the program sponsored by the maker of the drug. Academic groups outside the company have only reanalyzed or pooled that same trial data
Longest study	80 weeks, in the TRIUMPH-1 and TRIUMPH-2 phase 3 trials [20], [21]
Approval	Still under study. Not approved by the FDA, the EMA or the MHRA
Do the results agree	Yes. Higher doses gave larger effects in both the obesity group and the type 2 diabetes group. Safety matched the wider class of incretin agonist drugs

Incretins are gut hormones such as GLP-1 and GIP.

How it might work

Retatrutide is one peptide backbone that switches on three different receptors. All three are G-protein-coupled receptors, a large family of receptors on the surface of cells. In the published pharmacology, each of the three is tied to a different part of how the body controls metabolism. Researchers have proposed that having all three is what sets it apart from incretin drugs that hit one receptor or two [5].

The GLP-1 part

Across incretin research as a whole, the GLP-1 receptor is the best described of the three. The retatrutide pharmacology papers link it to appetite signals and to slower emptying of the stomach. These are thought to be main causes of the weight effects seen in human trials [5].

The GIP part

What the GIP receptor adds is more openly argued over.

• In mouse models, switching on the GIP receptor improved unhealthy blood fat levels and lowered markers of artery plaque. It did this without any change in body weight. That points to a metabolic effect apart from curbing appetite [8].
• Other lab research found something odd. Switching on the GIP receptor for a long time can dull GIP receptor signaling in fat cells. In practice that looks like blocking the receptor. Researchers named this the “GIP receptor agonism paradox”. Both switching the receptor on and blocking it have been linked to good metabolic effects, in different experiments [4].

This is still an open research question, not a settled one.

The glucagon part

The glucagon part is what most clearly separates retatrutide from drugs that hit only GLP-1 and GIP.

Basic hormone research has shown that glucagon receptor signaling is essential for adaptive thermogenesis in brown fat. Thermogenesis means making heat. That supports energy use as one way the drug could work [1].

In the research on single-molecule agonists, this part is proposed to add to how the liver handles fat and to energy burned at rest. That would sit next to the appetite effects of the GLP-1 and GIP parts [2]. Direct human data that isolate what the glucagon receptor adds in retatrutide itself are still limited.

How the molecule is built

Like other modern peptide polyagonists, it starts from a core peptide chain. A fatty acid part is attached to that chain. That part helps the molecule bind to albumin, a protein in blood. The binding stretches its half-life, the time it takes for half of it to leave the bloodstream. The half-life becomes long enough to allow one dose a week. Papers on tuning peptide polyagonists lay out this approach in detail [3].

The compound is not equally strong at all three receptors. Its makers tuned its strength at each one on purpose during development. The first discovery pharmacology paper describes the exact balance they chose [5].

What the studies found

These are the main published human results so far. They come from two phase 2 trials and three phase 3 trials.

Obesity, phase 2

• The trial. This trial enrolled 338 adults who had obesity, or overweight with a related health problem. They got a placebo or one of four once-weekly dose levels for 48 weeks: 1 mg, 4 mg, 8 mg or 12 mg. The 4 mg and 8 mg levels each had two starting doses, so there were six drug groups in all. The trial was randomized and double-blind. Body weight fell more at higher doses. At 48 weeks, the average drop was 24.2% in the 12 mg group and 2.1% with placebo. In the 12 mg group, 83% of people lost 15% or more of their weight [6].
• Conference report. A later report on this trial backed up the 48-week results. It added more detail on safety and on how people tolerated the drug, drawn from everyone in the study [10].
• Side effects. The ones reported most often were in the gut: nausea, diarrhea, vomiting and constipation. They were mostly mild to moderate, and they clustered in the weeks when the dose was being raised. That fits what is known about how people tolerate incretin drugs as a class [6].
• Letters. Scientific letters printed after the trial went further into how to read its safety and effect data [9].

Type 2 diabetes, phase 2

• The trial. A separate trial tested the drug in adults who had type 2 diabetes. It was randomized and double-blind, with a placebo group and an active drug group to compare against. Treatment lasted 36 weeks. Blood sugar control, measured as HbA1c, improved by a clinically meaningful amount. Body weight also fell. Both happened across the range of doses tested [7].
• Pooled data. A systematic review and meta-analysis put the trial data on hand together. It concluded that both the benefits and the side effects were broadly alike in the obesity group and the type 2 diabetes group [13]. A separate overview of the evidence in type 2 diabetes and obesity said much the same [15].

Phase 3 trials

• TRIUMPH-1, obesity. This trial enrolled 2,339 adults who had obesity but not diabetes. They got 4 mg, 9 mg or 12 mg once a week, or a placebo, for 80 weeks. Average weight loss was 17.6%, 23.7% and 25.0% at the three doses. It was 3.9% with placebo. Knee pain eased in people who had knee osteoarthritis. People who had obstructive sleep apnea had fewer breathing pauses in their sleep [20].
• TRIUMPH-2, obesity with type 2 diabetes. This trial enrolled 1,152 adults and used the same doses for 80 weeks. Average weight loss was 11.9%, 16.8% and 18.8% at the three doses. It was 5.1% with placebo [21].
• TRANSCEND-T2D-1, type 2 diabetes. This 40-week trial enrolled 537 adults whose diabetes was not controlled by diet and exercise. HbA1c fell by 1.69 to 1.94 percentage points with the drug and by 0.81 with placebo. Body weight fell by 11.5% to 15.3% with the drug and by 2.6% with placebo [19].

Fat and lean mass

• A sub-study of the type 2 diabetes trial looked just at what the body is made of. It used DXA scans, short for dual-energy X-ray absorptiometry. With retatrutide, people lost a larger share of fat mass than of lean mass. Researchers see that as a good result when they judge incretin weight-loss drugs [14].

Heart and metabolic markers

• A systematic review and meta-analysis of randomized controlled trials reported lower blood pressure with retatrutide. It also reported better blood fat measures, among them triglycerides and LDL cholesterol [17].
• Some reviews place the drug within research on cardiovascular-kidney-metabolic (CKM) syndrome. They point to these heart and metabolic results as a reason to keep studying it for more than body weight [16]. This is a way of framing the research. It is not an established medical use.

Safety

In human trials

• Gut problems were the side effects seen most often across the phase 2 trials. These were nausea, diarrhea, vomiting and constipation. They were mostly mild to moderate and most common while the dose was being raised [6], [7].
• In the phase 3 trials, gut problems were again the most common side effects [19], [20], [21]. In TRIUMPH-2, low blood pressure and dysesthesia, an odd or unpleasant feeling in the skin, were more common with the drug than with placebo. More people on the 9 mg and 12 mg doses stopped treatment because of side effects [21].
• A 2025 pooled analysis of the earlier trials found no new or unexpected safety signal. It saw only the known gut pattern shared with other GLP-1 drugs [13].
• Changes in blood pressure and blood fats seen with the drug so far have moved in a good direction. They have not raised safety concerns [17].

What is not known

• Peer-reviewed research has not yet reported on long-term safety past 80 weeks of steady dosing.
• Safety and effect have not been shown in groups the trials left out. Examples are teenagers, pregnancy, and people with serious liver or kidney problems.
• This guide’s review of the published research found no formal drug interaction studies.
• Work not paid for by the maker is still limited.
• Published human data have not yet fully separated what the glucagon receptor adds in people from what the GLP-1 and GIP parts add.

Legal status in the US

• Not FDA approved. Retatrutide has no approval for any medical use from the FDA. The same is true of the EMA in Europe and the MHRA in the UK.
• Banned in sport. It is a peptide hormone that switches on receptors. That class of compound falls under class S2 of the World Anti-Doping Agency Prohibited List (peptide hormones, growth factors, related substances and mimetics). S2 substances are banned at all times, both in competition and out of it.
• Research use. Suppliers provide it strictly for use in laboratory research.

Limits of the research

1. Phase 3 results are new. The first phase 3 trials were published in 2026. Other phase 3 trials had not been published when this guide was last reviewed.
2. The maker paid for the trials. All the primary trial data found for this guide come from the research program sponsored by the maker of the compound. No independent academic trial has been published yet.
3. Little long-term data. The longest published treatment found lasted 80 weeks. The peer-reviewed record does not yet describe effects, or how well people tolerate it, past that point.
4. The cause is not fully pinned down. Lab research supports each of the three receptor parts. Sorting out the exact human share of each one inside the combined effect is still an open question. That is most true of the glucagon receptor part.
5. Narrow groups. Trials so far enrolled adults who had obesity or type 2 diabetes. The results should not be stretched to other groups or settings.
6. Possible bias in what gets published. This cannot be ruled out. It applies to any drug research that comes mainly from trials the developer designed and reported.

Phase 2 and phase 3 trials show large weight loss and better blood sugar with retatrutide. Long-term safety data and independent trials are still missing.

References

Selected peer-reviewed references, each verified against the CrossRef API before inclusion. Ordered by date of publication.

1. Kinoshita K, Ozaki N, Takagi Y, Murata Y, et al. (2014). Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue. Endocrinology, 155(9), 3484–3492. DOI: 10.1210/en.2014-1175
2. Tschöp M, Finan B, Clemmensen C, Gelfanov V, et al. (2016). Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism, 24(1), 51–62. DOI: 10.1016/j.cmet.2016.06.021
3. Knerr P, Finan B, Gelfanov V, Perez-Tilve D, et al. (2018). Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorganic & Medicinal Chemistry, 26(10), 2873–2881. DOI: 10.1016/j.bmc.2017.10.047
4. Killion E, Chen M, Falsey J, Sivits G, et al. (2020). Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications, 11, 4981. DOI: 10.1038/s41467-020-18751-8
5. Coskun T, Urva S, Roell W, Qu H, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.e9. DOI: 10.1016/j.cmet.2022.07.013
6. Jastreboff A, Kaplan L, Frias J, Wu Q, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. DOI: 10.1056/NEJMoa2301972
7. Rosenstock J, Frias J, Jastreboff A, Du Y, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. DOI: 10.1016/S0140-6736(23)01053-X
8. Sachs S, Götz A, Finan B, Feuchtinger A, et al. (2023). GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology, 22, 129. DOI: 10.1186/s12933-023-01940-2
9. Correspondence (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389(17), 1628–1630. DOI: 10.1056/nejmc2310645
10. Jastreboff A, Kaplan L, Frias J, Wu Q, et al. (2024). Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial. Diabetologie und Stoffwechsel, 19(S01), S77–S78. DOI: 10.1055/s-0044-1785389
11. Tetelbaun L, Mullally J, Frishman W (2024). The First Triple Agonist for Antiobesity: Retatrutide. Cardiology in Review. DOI: 10.1097/CRD.0000000000000793
12. Kaur M, Misra S (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology, 80(5), 669–676. DOI: 10.1007/s00228-024-03646-0
13. Tewari J, Qidwai K, Tewari A, Kaur S, et al. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 18(1-2), 51–66. DOI: 10.1080/17512433.2025.2450254
14. Coskun T, Wu Q, Schloot N, Haupt A, et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, 13(8), 674–684. DOI: 10.1016/S2213-8587(25)00092-0
15. Panou T, Gouveri E, Popovic D, Papanas N (2026). Retatrutide in type 2 diabetes mellitus and obesity: an overview. Expert Review of Clinical Pharmacology, 19(4), 313–339. DOI: 10.1080/17512433.2026.2642415
16. Pillai A, Godin S, Frishman W, Aronow W (2026). Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in Review. DOI: 10.1097/CRD.0000000000001310
17. Simental-Mendia L, Barragan-Zuniga L, Reyes-Avitia V (2026). Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Pressure & Cardiovascular Prevention. DOI: 10.1007/s40292-026-00812-6
18. Giblin K, Kaplan L, Somers V, Le Roux C, et al. (2026). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 28(1), 83–93. DOI: 10.1111/dom.70209
19. Bajaj H, Welch M, Shah P, Luna E, et al. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet, 407(10546), 2402–2413. DOI: 10.1016/S0140-6736(26)00967-0
20. Jastreboff A, Kaplan L, Davies M, Wilding J, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Online ahead of print. DOI: 10.1056/NEJMoa2604169
21. Bellido V, le Roux C, Ekinci E, Bjornstad P, et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Online ahead of print. DOI: 10.1016/S0140-6736(26)01861-1